VIRAMUNE XR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Mar 2011
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIRAMUNE XR is an extended-release oral tablet small molecule approved in 2011 by Boehringer Ingelheim. The specific indication and mechanism of action are not detailed in available data, but the product is classified as a non-nucleoside reverse transcriptase inhibitor (NNRTI) based on historical VIRAMUNE formulations. This formulation represents an advancement in dosing convenience for chronic viral therapy.
LOE Approaching2.7 years to LOE
Product is in late-stage lifecycle with 2.7 years until loss of exclusivity (March 2029), signaling a consolidating and smaller commercial team focused on maximizing remaining patent-protected sales.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Worked on VIRAMUNE XR at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.